Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice

Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban
Ying ZhangGang Xu

Abstract

Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction (UUO) was used to establish a different renal fibrosis model. PPAR? agonist pioglitazone was administrated by oral gavage and saline was used as control. At 7th and 14th day after the operation, mice were sacrificed for fibrosis test and T lymphocytes subsets test. Unexpectedly, through MASSON staining, immunohistochemistry for α-SMA, and Western blotting for a-SMA and PDGFR-β, we found that pioglitazone failed to attenuate renal fibrosis in UUO mice. However, flow cytometry showed that pioglitazone down-regulated Th1 cells, and up-regulated Th2 cells, Th17 cells and Treg cells. But the Th17/Treg ratio had no significant change by pioglitazone. Real-time PCR results showed that TGF-β and MCP-1 had no significant changes, at the same time, CD4(+) T cells associated cytokines were partially regulated by pioglitazone pretreatment...Continue Reading

References

Jul 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sandrine HenriAlain J Dessein
Nov 6, 2003·International Archives of Allergy and Immunology·Akira SaitoHajime Takizawa
Jun 16, 2005·Kidney International·Rajiv AgarwalMerfake H Semret
Nov 18, 2005·Journal of the American Society of Nephrology : JASN·Masaomi Nangaku
Dec 7, 2007·Journal of the American Society of Nephrology : JASN·Christian A SchneiderErland Erdmann
Oct 3, 2009·Journal of the American Society of Nephrology : JASN·Hai-Chun YangAgnes B Fogo
Jan 7, 2010·Journal of Korean Medical Science·Jee-Young HanDae-Ryong Cha
Jun 18, 2010·Kidney International·Thomas T TapmeierWilson Wong
Sep 25, 2010·Journal of the American Society of Nephrology : JASN·Michael Zeisberg, Eric G Neilson
Apr 9, 2011·Journal of the American Society of Nephrology : JASN·Arthur C K Chung, Hui Y Lan
Sep 14, 2011·International Immunopharmacology·Yi LiWeihua Feng
Jan 27, 2012·Scandinavian Journal of Clinical and Laboratory Investigation·Fu-Jun LinXiang-Ru Wu
Apr 18, 2012·The Journal of Surgical Research·Honglin HuXueming Huang
Apr 20, 2012·Trends in Endocrinology and Metabolism : TEM·Bertrand CariouBart Staels
Jun 23, 2012·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·F PistroschS R Bornstein
Aug 7, 2012·Cancer Immunology, Immunotherapy : CII·Stephanie K BuntMichael A Hollingsworth
Sep 19, 2012·Journal of Applied Toxicology : JAT·Cristiano R JesseCristina W Nogueira
Oct 12, 2012·American Journal of Nephrology·Lili LiuSheng Chen
May 24, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Su-Mi KimJu-Young Moon
Jun 3, 2015·Journal of the American Society of Nephrology : JASN·Norihiko Sakai, Takashi Wada

❮ Previous
Next ❯

Citations

May 16, 2021·Acta Pharmacologica Sinica·Yuan-Yuan ChenSen Zhang
Sep 25, 2021·Cellular & Molecular Immunology·Yunfeng ZhouTuo Deng

❮ Previous
Next ❯

Related Concepts